LY22-02f

Efficacy and safety of CD19 directed CAR T-cell therapy for high grade B-cell lymphoma.

Study #: LY22-02f

Study Status: Published

Presentation(s)

2025, Tandem (Poster)

Chimeric antigen receptor T-cell therapy for high grade B-cell lymphoma NOS.

Citation

Hossain NM, Ahn KW, Patel J, Lian Q, Bilal Abid M, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF.

British Journal of Haematology. 2025, Sep 01: 207(3): 207(3):1011-1018. doi: 10.1111/bjh.70020. Epub 2025, Jul 22. PMCID:.

PubMed

PMID: 40693472

Abstract